Latest News

PLYMOUTH MEETING, PA  — The National Comprehensive Cancer Network® (NCCN®) today announced publication of new NCCN Guidelines for Patients®: Small Bowel Adenocarcinoma. This free resource for people facing cancer and caregivers is focused on a rare cancer type that typically occurs in the small intestine, where routine screening is impossible,...
To accelerate the development of gene therapies for the 30 million Americans who have been diagnosed with a rare disease, in October 2021 the National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), 10 pharmaceutical companies, and five nonprofit organizations announced the creation of the Bespoke Gene Therapy Consortium (BGTC)....
EAST HANOVER, N.J. — Novartis today presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), an investigational Factor B inhibitor of the alternative complement pathway, in patients with IgA nephropathy (IgAN). In the analysis, patients treated with Fabhalta achieved a 38.3% (p<0.0001) proteinuria reduction...
Okayama, Japan – Pancreatic cancer, recognized as one of the deadliest cancers, poses a persistent challenge for medical professionals globally due to its aggressive behavior and resistance to conventional therapies. The dense fibrotic tissue surrounding pancreatic tumors acts as a significant barrier, hindering the delivery of macromolecular drugs such as...
Reston, VA — A novel imaging approach, 68Ga-pentixafor PET/CT, has been shown to accurately identify sub-types of primary aldosteronism (an adrenal gland disorder), outperforming traditional methods for diagnosis. Reported in the January issue of The Journal of Nuclear Medicine, this detailed imaging technique provides a clearer picture of the adrenal glands, helping...